FDA granted an Orphan Drug Designation to ImMucin for the treatment of multiple myeloma, developed by Vaxil Bio.
GEORGETOWN LOMBARDI Comprehensive Cancer Center and John Theurer Cancer Center, part of Hackensack University Medical Center, developed a joint cancer research agenda as part of a multi-year plan to form a NCI-recognized cancer consortium.
FDA approved Iressa (gefitinib) for patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
ACT for NIH added seven members to its advisory committee.
SYNEXUS opened three dedicated research centers in Bulgaria, Poland and Romania, bringing the total to nine centers in Eastern Europe and a total network of 25 across Europe and Africa.
MARYANN ROEFARO was named co-chair of the Community Oncology Alliance Administrators' Network.
CITY OF HOPE established an endowed professorship with a $1.5 million gift from the Norman and Sadie Lee Foundation. The professorship will be used to advance research, education and clinical activities in support of head and neck cancer treatment.
Eli Lilly and Co. and Immunocore Ltd. entered into an immunotherapy-based clinical trial collaboration to explore the utility of Immunocore's lead T cell receptor-based investigational therapeutic, IMCgp100, in combination with Lilly's galunisertib (LY2157299) and merestinib (LY2801653).
THE ASSOCIATION OF COMMUNITY CANCER CENTERS launched the Institute for Clinical Immuno-Oncology, an initiative focused on facilitating the adoption of immuno-oncology in the community cancer setting.
THE AMERICAN COLLEGE OF RADIOLOGY launched the Commission on Patient Experience, which will be chaired by James Rawson, of Augusta, Ga.
